In summary, previous studies into deoxynucleoside supplementation as a therapy for mitochondrial disease due to pathogenic RRM2B variants have been performed on in vitro models that focus mainly on manipulation of mtDNA copy number [28]. Here, RRM2B is linked to mitochondrial disease.